For three years the case for gray-market GLP-1s was arithmetic: the brand cost more than a car payment. That arithmetic broke in 2026. If your content, your protocol, or your budget still assumes compounded is dramatically cheaper, it is running on stale numbers.
What changed, in order
| Date | Event |
|---|---|
| Nov 2025 | White House announces most-favored-nation pricing deal with Lilly and Novo |
| Feb 5, 2026 | TrumpRx.gov launches |
| Feb 23, 2026 | LillyDirect Zepbound self-pay tiers take effect at $299 / $399 / $449 by dose |
| Mar 3, 2026 | FDA issues 30 warning letters to telehealth companies over compounded-GLP-1 marketing |
| Apr 1, 2026 | FDA approves Foundayo (orforglipron), the first oral non-peptide GLP-1 |
| Jul 1, 2026 | Medicare GLP-1 Bridge pilot begins — $50/mo copay |
The prices that matter
TrumpRx.gov is a federal portal that routes to the manufacturers' own direct-pay channels. Verified in July 2026, it listed injectable Wegovy and Ozempic at $199 per month, the Wegovy pill at $149, and Zepbound at $299 — against displayed before-prices of $1,349, $1,028, and $1,087 respectively. Those are lowest-dose starting prices; higher doses cost more.
Foundayo (orforglipron) launched with announced pricing of $149 per month at the lowest dose, scaling up to $399 at higher doses.
The Medicare GLP-1 Bridge, live since July 1, caps eligible Part D enrollees at a $50 monthly copay through the end of 2027. Covered: Foundayo tablets, Wegovy pills and injections, Zepbound KwikPens. Zepbound single-use pens and vials are excluded — a detail worth reading carefully before assuming coverage.
“Compounded is 80% cheaper than brand” was accurate in 2023. Against a $199 injectable or a $149 oral through a legal channel, with real trial data and pharmacy-grade manufacturing behind it, the economic argument for the gray market in this specific class has largely collapsed. Any content still running that comparison is misinforming its readers.
What this does to the research channel
Be precise about scope, because the effect is not uniform.
For GLP-1s specifically, the case is weak now. A brand product with registration trials, consistent manufacturing, and a $149–$299 monthly price defeats an untested vial on almost every axis that matters. Price was doing all the work, and price stopped doing it.
For everything else, nothing changed. BPC-157, TB-500, MOTS-c, and the rest have no approved brand equivalent at any price. The July 2026 PCAC recommendations might eventually open a prescription pathway for six of them, on a rulemaking timeline commonly estimated at 8 to 24 months. Until then there is no legal retail alternative to compare against.
The regulatory pressure is real
The March 2026 warning letters to telehealth companies marketing compounded GLP-1s were not a formality. With the shortage designation resolved and the brand shortage argument gone, the compounding justification that sustained the market has largely evaporated for this class.
The practical read
If you are on compounded semaglutide or tirzepatide right now, price the brand channel before your next refill. There is a reasonable chance you are paying more for less oversight, which was not true two years ago and is the kind of change that people miss because they set up their sourcing once and stopped checking.
If you are running non-GLP-1 compounds, this news does not apply to you and no one should tell you otherwise.
Research-use suppliers
Frequently Asked
It depends entirely on channel. On the TrumpRx platform, verified in July 2026, injectable Wegovy and Ozempic were listed at $199 per month and the Wegovy pill at $149, against displayed before-prices well over $1,000. Zepbound was listed at $299. Higher doses cost more, so confirm the price for your specific dose.
An 18-month pilot running July 1, 2026 through December 31, 2027 that lets eligible Part D enrollees access certain GLP-1 medications for weight loss at a $50 monthly copay. Covered products include Foundayo (orforglipron) tablets, Wegovy pills and injections, and Zepbound KwikPens. Zepbound single-use pens and vials are excluded.
Frequently not, once you count the consult and the shipping, and the gap has narrowed dramatically. The FDA has also been actively pursuing compounded-GLP-1 marketing, issuing a batch of warning letters to telehealth companies in March 2026.
Lilly’s oral non-peptide GLP-1 agonist, approved as Foundayo on April 1, 2026. Lilly’s announced pricing was $149 per month at the lowest dose with higher doses priced up to $399.
Indirectly but meaningfully. The old argument for the gray market was overwhelmingly economic. When the brand product with actual trial data behind it costs $149–$299 a month through a legal channel, that argument gets much harder to make for the GLP-1 class specifically.